Vertex Pharmaceuticals (VRTX) Current Deferred Revenue (2009 - 2017)

Vertex Pharmaceuticals' Current Deferred Revenue history runs 9 years deep, the most recent figure standing at $5.2 million for Q4 2017.

• On a quarterly basis, Current Deferred Revenue fell 13.92% year-over-year to $5.2 million in Q4 2017; TTM through Dec 2017 was $5.2 million, a 13.92% decrease from a year earlier, with the FY2017 full-year figure at $5.2 million, down 13.92% from the prior year.
• Current Deferred Revenue slipped to $5.2 million in Q4 2017 per VRTX's latest filing, from $13.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $35.5 million in Q1 2013 and bottomed at $5.2 million in Q4 2017.
• The 5-year median for Current Deferred Revenue is $15.4 million (2015), against an average of $17.5 million.
• Across the five-year window, Current Deferred Revenue slumped 63.15% in 2016 and soared 40.62% in 2017, its largest moves.
• Year by year, Current Deferred Revenue stood at $21.5 million in 2013, then dropped by 18.79% to $17.5 million in 2014, then slipped by 6.71% to $16.3 million in 2015, then slumped by 63.15% to $6.0 million in 2016, then decreased by 13.92% to $5.2 million in 2017.
• Per Business Quant, the three latest VRTX Current Deferred Revenue figures stand at $5.2 million (Q4 2017), $13.0 million (Q3 2017), and $7.3 million (Q2 2017).